SEARCH:   Advanced

Blood, 1 September 2008, Vol. 112, No. 5, pp. 1658-1661. Prepublished online as a Blood First Edition Paper on June 30, 2008; DOI 10.1182/blood-2008-04-151563. This Article Full Text (PDF) All Versions of this Article: blood-2008-04-151563v1 112/5/1658    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gerstner, E. R Articles by Batchelor, T. T Search for Related Content PubMed PubMed Citation Articles by Gerstner, E. R Articles by Batchelor, T. T Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 14, 2008 Accepted June 16, 2008 CNS Hodgkin lymphoma Elizabeth R Gerstner*, Lauren E. Abrey, David Schiff, Andres J. M. Ferreri, Andrew Lister, Silvia Montoto, Richard Tsang, Eckhard Thiel, Francesc Graus, Dirk Behringer, Gerald Illerhaus, Susan Weaver, Patrick Wen, Alfredo Voloschin, Nancy Lee Harris, and Tracy T Batchelor Massachusetts General Hospital, Boston, MA, United States Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York City, NY, United States Neuro-Oncology, University of Virginia, Charlottesville, VA, United States Hematology-Oncology, San Raffaele H Scientific Institute, Milan, Italy Hematology-Oncology, St. Bartholomew's Hospital, London, United Kingdom Radiation Oncology, Princess Margaret Hospital, Toronto, Canada Hematology-Oncology, Charite-Campus Benjamin Franklin, Berlin, Germany Hematology-Oncology, Hospital Clinic, Barcelona, Spain Hematology-Oncology, Augusta-Kranken-Anstalt, Bochum, Germany Hematology-Oncology, University Hospital Freiburg, Freiburg, Germany Neuro-Oncology, Albany Medical Center, Albany, NY, United States Neuro-Oncology, Dana Farber Cancer Institute, Boston, MA, United States Neuro-Oncology, Medical College of Georgia, Augusta, GA, United States * Corresponding author; email: egerstner{at}partners.org. Central nervous system (CNS) involvement by Hodgkin lymphoma (HL) is rare. As a result, there is limited guidance for clinicians on how to manage these patients. Detailed information was collected on 16 patients, the largest number to date, with meningeal or parenchymal CNS-HL confirmed by histopathology (15) or CSF (1). Eight patients presented with CNS-HL at diagnosis, 2 of whom had isolated CNS disease, while 8 patients developed CNS-HL at relapse. Patients received a range of treatments including surgery or radiation alone, radiation with chemotherapy, or chemotherapy alone. Median overall survival for all 16 patients was 60.9 months from first diagnosis of HL (systemic or CNS) and 43.8 months from diagnosis of CNS-HL. Although a majority of patients have died, long-term survival is possible in patients who achieve a complete response to treatment- particularly those who present with CNS involvement or involvement of the CNS is the sole site of relapsed disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020